Adicet Bio Net Income

The latest net income for ACET is $-99M as of June 2026. That compares with $-120M in the prior-year period — up 16.6% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Adicet Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, ACET's net income moved from $-120M to $-99M — a 16.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adicet Bio's operating scale or balance-sheet position.

Against Healthcare companies, ACET currently prints $-99M for net income, while the sector average sits near $16B. That is roughly 100.6% below the sector mean. Large gaps often invite a closer look at Adicet Bio's growth, margins, and balance sheet.

A net income figure of $-99M for ACET is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting ACET's net income ($-99M), review year-over-year change from $-120M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.